Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Riccardo Sartoris(Hôpital Beaujon), Kornelius Schulze(Universität Hamburg), Antonio D’Alessio(Hammersmith Hospital), Fabian Finkelmeier(Goethe University Frankfurt), Katharina Pomej(Medical University of Vienna), Florian Hucke(Klinikum Klagenfurt), Rudolf Stauber(Medical University of Graz), Johann von Felden(Universität Hamburg), A. Krall(Medical University of Graz), Sabrina Sidali(Hôpital Beaujon), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Vera Himmelsbach(Goethe University Frankfurt), AR Siebenhüner(University Hospital Zurich), Jörg Trojan(Goethe University Frankfurt), Nuh N. Rahbari(Technische Universität Dresden), Sara De Dosso(Institute of Oncology Research), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Arndt Vogel(Princess Margaret Cancer Centre), Mohamed Bouattour(Hôpital Beaujon), Michael Trauner(Medical University of Vienna), Henning Wege(Universität Hamburg), Maxime Ronot(Hôpital Beaujon), Kateryna Shmanko(Johannes Gutenberg University Mainz), Andreas Teufel(Johannes Gutenberg University Mainz), Pompilia Radu(University of Bern), Lorenz Balcar(Medical University of Vienna), Wei‐Fan Hsu(China Medical University), Matthias P. Ebert(Heidelberg University), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Jean‐François Dufour(Universidad Iberoamericana), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Dirk Waldschmidt, Arndt Weinmann(Johannes Gutenberg University Mainz)
Cited by 2
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k